Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
October 10, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials...
Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference
October 05, 2023 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and...
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
September 12, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor...
Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine
September 11, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
[212Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumorsAdministration of fractionated doses of [212Pb]VMT-α-NET shows 100% survival in a robust model of metastatic...
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
August 30, 2023 08:17 ET
|
Perspective Therapeutics, Inc.
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two...
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
August 28, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will...
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
August 11, 2023 08:05 ET
|
Perspective Therapeutics, Inc.
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11,...
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
August 11, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a...
Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
August 09, 2023 08:05 ET
|
Perspective Therapeutics, Inc.
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company...
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
June 27, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company...